Dacarbazine
| File:Dacarbazine structure.png | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | 5 hours |
| Excretion | 40% renal (unchanged) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C6H10N6O |
| Molar mass | 182.18 |
|
WikiDoc Resources for Dacarbazine |
|
Articles |
|---|
|
Most recent articles on Dacarbazine Most cited articles on Dacarbazine |
|
Media |
|
Powerpoint slides on Dacarbazine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dacarbazine at Clinical Trials.gov Clinical Trials on Dacarbazine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dacarbazine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dacarbazine Discussion groups on Dacarbazine Patient Handouts on Dacarbazine Directions to Hospitals Treating Dacarbazine Risk calculators and risk factors for Dacarbazine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dacarbazine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Dacarbazine (da-KAR-ba-zeen) (brand names DTIC, DTIC-Dome; also known as DIC or Imidazole Carboxamide) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma and Hodgkin lymphoma. Antineoplastic drugs are drugs which interfere with cell growth and impede the formation of new tissue - in this case, tumor tissue. These drugs are also known as cytotoxic drugs. Dacarbazine belongs to the family of chemicals known as alkylating agents. Dacarbazine is normally administered by injection (a shot) or intravenous infusion (IV) under the immediate supervision of a doctor or nurse.
History
Dacarbazine gained FDA approval in May 1975 as DTIC-Dome. The drug was initially marketed by Bayer.
Side effects
Like many chemotherapy drugs, dacarbazine may have numerous serious side effects, because it interferes with normal cell growth as well as cancer cell growth. Among the most serious possible side effects are birth defects to children conceived or carried during treatment; sterility, possibly permanent; or immune suppression (reduced ability to fight infection or disease). Like most powerful drugs, it may produce more common side effects like nausea, fatigue, headache, etc.
Common uses
As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma.
Experimental
Dacarbazine + Oblimersen. In clinical trials for malignant melanoma.
Suppliers
Bayer continues to supply DTIC-Dome. There are also generic versions of dacarbazine available from APP, Bedford, Mayne Pharma and Sicor (Teva).
See also
Sources
- MedLine, U.S. National Institutes of Health, National Library of Medicine, http://www.nlm.nih.gov/medline/
- Cancerweb, http://cancerweb.ncl.ac.uk/cancerweb/
- OncoLink, http://oncolink.upenn.edu/
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Imidazoles